Genmab — December 2019
-
Mere m&a: Ett dotterbolag till amerikanska läkemedelsbolaget Merck lägger ett kontantbud på 20 dollar per aktie, motsvarande ett totalt värde på 2,7 miljarder dollar, för forskningsbolaget Arqule. Vid fredagens börsstängning i USA noterades Arqule till en aktiekurs om 9:665 dollar per aktie.
-
Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM https://www.youtube.com/watch?v=NfBDpLjI2mM
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
-CD3xCD20 (GEN3013) study as well as various daratumumab studies presented at the 61st Annual Meeting of the American Society of Hematology (ASH).